High blood-glucose levels could be linked to Alzheimer's risk

26 May 2015

High blood-glucose levels could be linked to the risk of Alzheimer’s disease and other forms of dementia, according to two recently-published studies.

One study found that patients with type 1 diabetes were more likely to have brain lesions and slower cognitive function than those without. Another preclinical study showed abnormally high blood-glucose levels were associated with increased production of amyloid beta in the brain.

The first study assessed the severity and volume of white matter hyperintensities and infarcts in 97 middle-aged patients with childhood-onset type 1 diabetes, and 81 adults without type 1 diabetes. The average age for the groups was 50 and 48 respectively. Results showed that patients in the diabetes group had more severe WMH and slower information processing, regardless of age, education and other factors, than those without the disease. Caterina Rosano, the lead researcher, said she was surprised by the findings given the fact the cohort of subjects was relatively young. She said: "These abnormalities will impact the speed with which your brain works, and how quickly information travels from one part of your brain to another."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical